The Mosaic Company MOS recently announced the launch of its newest biostimulant product, Neptunion, in China. MOS has been redefining growth with its new product launch that is expected to help crops address abiotic pressures such as drought, salinity and heat by adding stress-resistant properties into water-soluble fertilizers. MOS Biosciences’product line offers sustainable ag technology to provide farmers with solutions to improve yields while minimizing environmental impacts. Neptunion will play a crucial role in maximizing productivity and advancing MOS Biosciences’ business. Neptunion is also undergoing the registration process in India and Brazil. MOS stock has gained 9.5% over the past year compared with the industry’s 9.4% growth.Zacks Investment Research Image Source: Zacks Investment Research The company expects sales volumes for the Potash segment to be between 2.3 million tons and 2.5 million tons in the second quarter. For the Phosphate division, sales volumes are projected to be 1.7-1.9 million tons, reflecting strong demand globally. MOS also expects sales volumes for the second quarter to be around 30% higher than the first quarter for the Mosaic Fertilizantes unit. Distribution margin is forecast to be in the annual normalized $30-$40 per ton range. MOS’ Zacks Rank and Other Key Picks MOS currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the Basic Materials space are Akzo Nobel N.V. AKZOY, Newmont Corporation NEM and Idaho Strategic Resources, Inc. IDR. While AKZOY sports a Zacks Rank #1 (Strong Buy), NEM and IDR currently carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Akzo Nobel’s current-year earnings is pegged at $1.64 per share, implying a 17.14% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, while missing the rest. The Zacks Consensus Estimate for NEM’s current-year earnings is pegged at $3.92 per share, indicating a 12.64% year-over-year rise.Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed it in one, with an average surprise of 32.41%. NEM’s shares have soared 16% in the past year. The Zacks Consensus Estimate for IDR’s 2025 earnings is pegged at 78 cents per share, indicating a rise of 16.4% from year-ago levels. IDR’s earnings beat the consensus estimate in two of the trailing four quarters while missing the rest, with the average surprise being roughly 21.70%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Story Continues Newmont Corporation (NEM):Free Stock Analysis Report The Mosaic Company (MOS):Free Stock Analysis Report Akzo Nobel NV (AKZOY):Free Stock Analysis Report Idaho Strategic Resources, Inc. (IDR):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Mosaic Biosciences Unveils Biostimulant Product Neptunion in China
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...